Chris Biotech
Contributor since: 2013
Latest Articles
Marinus Pharmaceuticals: Significant Upside As A Result Of Secondary Offering, No Value Given To Late Stage Assets
Ziopharm: Why Is No One Modeling The 'New' Ziopharm?
Intrexon: Energy Segment Could Be Potential Blockbuster
Cerulean: Recently Announced Secondary Provides Interesting Opportunity
Intrexon: Back-End Economics Could Generate Huge Upside
Christopher & Banks: Temporary Headwind Creates Compelling Risk/Reward
Teva: Overlooked And Potentially Undervalued
U.S. Silica: Strong Demand Trends With Great Risk/Reward Profile
Willbros: Strong Industry Fundamentals Will Drive Margin Expansion
Superconductor Technologies: Potential Copper Wire Alternative Blockbuster
Chemtura: Major Restructuring With Earnings Growth On The Horizon
Energy Recovery, Inc.: Inflection Point Is Here
Alcobra: The Next Big Thing In ADHD
ANI Pharmaceuticals: Nothin' Generic About It
Cancer Genetics: Major Upside Through Proprietary Tests
Energy Recovery Inc.: The Little Company With The Big Technology
ATMI Inc: Restructuring Underway, The Best Is Yet To Come
ATMI: On The Cusp Of A Major Revaluation
Aceto: A Generic-Drug Growth Story